Seminars in Cancer Biology

Article	Citations
Small secretory proteins of immune cells can modulate gynecological cancers	499
Editorial Board	463
Advances in biology and novel treatments of SCLC	362
Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation	313
Expression of concern “Decoding T cell senescence in cancer: Is revisiting required?” [Semin. Cancer Biol. 108 (2025) 33–47]	282
Deregulated transcription factors in the emerging cancer hallmarks	258
Emerging applications of bacteria as antitumor agents	248
Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications	246
Critical DNA damaging pathways in tumorigenesis	239
Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator	234
Multifaceted role of chemokines in solid tumors: From biology to therapy	206
Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation	204
Targeting Hippo signaling pathway by phytochemicals in cancer therapy	200
Erratum to “RNA regulatory mechanisms controlling TGF-β signaling and EMT in cancer” [Semin. Cancer Biol. 102–103 (2024) 4–16]	197
Origins and molecular effects of hypoxia in cancer	193
Association of Chlamydia and Mycoplasma infections with susceptibility to ovarian cancer: A systematic review and meta-analysis	192
Anticancer properties of chimeric HDAC and kinase inhibitors	190
Editorial Board	188
Special issue: Deregulated transcription factors in the cancer therapeutic challenges: An update on cancer stemness features	168
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy	167
The impact of obesity and lipids on cancer: Insights into mechanisms and potential interventions	165
Editorial Board	165
Expression of concern: “Combined targeting of senescent cells and senescent macrophages: A new idea for integrated treatment of lung cancer” [Semin. Cancer Biol. 106–107 (2024) 43–57]	154
Molecular targets of tyrosine kinase inhibitors in thyroid cancer	152
Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer	148

Innovative trial design in precision oncology	147
Enhancing head and neck tumor management with artificial intelligence: Integration and perspectives	146
Cracking the resistance code: The molecular reclassification of cancer and precision therapy strategies	144
Gut microbes in gastrointestinal cancers	138
Excess body weight and postmenopausal breast cancer: Emerging molecular mechanisms and perspectives	134
Genome chaos: Creating new genomic information essential for cancer macroevolution	127
Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy	126
Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics?	124
The IL-1 family in tumorigenesis and antitumor immunity	122
Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse	121
Extracellular vesicles associated microRNAs: Their biology and clinical significance as biomarkers in gastrointestinal cancers	121
Immune cellular components and signaling pathways in the tumor microenvironment	120
Metabolic landscape and rewiring in normal hematopoiesis, leukemia and aging	119
The emerging role of metabolic interventions in uveal melanoma	119
Editorial Board	118
Anticancer natural products targeting immune checkpoint protein network	116
New biological and immunological approaches to cancer therapy: Basic and clinical aspects	116
Reprogramming of glycolysis by chemical carcinogens during tumor development	113
Curcumin and colorectal cancer: An update and current perspective on this natural medicine	112
Regulation of the aryl hydrocarbon receptor in cancer and cancer stem cells of gynecological malignancies: An update on signaling pathways	111
Lipid metabolism in cancer is regulated by the integrated natural product–miRNA–target axis	110
How far have we explored fungi to fight cancer?	109
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors	107
Multi-omic markers of intraductal papillary mucinous neoplasms progression into pancreatic cancer	105
Modulation of the tumor microenvironment by natural agents: implications for cancer prevention and therapy	105
Targeting the “undruggable”: RNA-binding proteins in the spotlight in cancer therapy	103
Vibrational spectroscopy for decoding cancer microbiota interactions: Current evidence and future perspective	102
Insight into the role of multiple signaling pathways in regulating cancer stem cells of gynecologic cancers	101
Therapy-induced modulation of extracellular vesicles in hepatocellular carcinoma	101
Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems	100
Atrial fibrillation in cancer patients: Epidemiology, identification and management	100
Cellular stress responses and metabolic reprogramming in cancer progression and dormancy	100
The role of deiodinases on metabolic alteration in cancer	99
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine	99
Expression of concern “Immunosenescence in digestive system cancers: Mechanisms, research advances, and therapeutic strategies” [Semin. Cancer Biol. 106–107 (2024) 234–250]	99
Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools	98
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer	97
Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics	95
Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics	95
Editorial Board	94
Editorial Board	92
Analytical demands to use whole-genome sequencing in precision oncology	91
The role of RNA processing and regulation in metastatic dormancy	89
Mechanisms and applications of apolipoproteins and apolipoprotein mimetic peptides: Common pathways in cardiovascular disease and cancer	89
BubR1 and SIRT2: Insights into aneuploidy, aging, and cancer	88
Cytotoxic activity of l-lysine alpha-oxidase against leukemia cells	88
The foundational framework of tumors: Gametogenesis, p53, and cancer	87
Microorganisms in cancer tertiary lymphoid structure formation	86
Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment	86
Transcription networks rewire gene repertoire to coordinate cellular reprograming in prostate cancer	85

The microbiome-immune cell interaction network: Advancing tumor immunotherapy	84
Role of ubiquitination-driven metabolisms in oncogenesis and cancer therapy	84
Drivers of centrosome abnormalities: Senescence progression and tumor immune escape	83
Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications	81
Clinical utility of whole-genome sequencing in precision oncology	80
Metabolic reprogramming of tumor microenviroment by engineered bacteria	80
Microbiota and lung cancer	77
Plant lectins and their usage in preparing targeted nanovaccines for cancer immunotherapy	76
Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders	75
Advancements in small cell lung cancer	75
Functionalized-DNA nanostructures as potential targeted drug delivery systems for cancer therapy	75
Chaperonins in cancer: Expression, function, and migration in extracellular vesicles	74
The role of tumor microenvironment and exosomes in dormancy and relapse	74
Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling	73
Beyond cardiovascular health: The pharmacotherapeutic potential of statins in oncology	73
Sanitation enzymes: Exquisite surveillance of the noncanonical nucleotide pool to safeguard the genetic blueprint	73
Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer	73
CRISPR/Cas mediated epigenome editing for cancer therapy	72
Pattern recognition of tumor dormancy and relapse beyond cell-intrinsic and cell-extrinsic pathways	72
Paradoxes of cancer: Survival at the brink	71
Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment	71
Holistic immunomodulation for small cell lung cancer	70
Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme	70
Urinary microbiota and bladder cancer: A systematic review and a focus on uropathogens	69
Targeting p53 for the treatment of cancer	69
Excess body weight: Novel insights into its roles in obesity comorbidities	69
Microbes in gynecologic cancers: Causes or consequences and therapeutic potential	68
Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications	68
Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer	68
Novel molecular regulators of breast cancer stem cell plasticity and heterogeneity	68
Chemopreventive effects of anthocyanins on colorectal and breast cancer: A review	68
Anticancer activity of lactic acid bacteria	67
Editorial Board	66
Targeting tumor cell senescence and polyploidy as potential therapeutic strategies	66
Editorial Board	66
SR-BI as a target of natural products and its significance in cancer	65
Special Issue: Epigenetic regulation of cancer progression: Promises and progress	64
Editorial Board	63
Characterizing and exploiting the many roles of aberrant H2B monoubiquitination in cancer pathogenesis	63
Deregulated transcription factors and poor clinical outcomes in cancer patients	62
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges	62
Microbial metabolites for cancer immunotherapy: Current evidence and future directions	62
Accelerating antibody discovery and design with artificial intelligence: Recent advances and prospects	61
The intricate role of adipokines in cancer-related signaling and the tumor microenvironment: Insights for future research	61
Thematic issue ‘tumor glycolysis’	61
Exosome-based nanomedicine for cancer treatment by targeting inflammatory pathways: Current status and future perspectives	60
Beyond cell cycle regulation: The pleiotropic function of CDK4 in cancer	60
Human cell polyploidization: The good and the evil	59
Obesity and main urologic cancers: Current systematic evidence, novel biological mechanisms, perspectives and challenges	59
The crucial role of epigenetic regulation in breast cancer anti-estrogen resistance: Current findings and future perspectives	59
Non-coding genome in small cell lung cancer between theoretical view and clinical applications	59
TGF-β, EMT, and resistance to anti-cancer treatment	59
The impact of VEGF on cancer metastasis and systemic disease	59
Extracellular vesicles as source for the identification of minimally invasive molecular signatures in glioblastoma	58
The role of RNA-binding proteins in the processing of mRNAs produced by carcinogenic papillomaviruses	58
The intricate nature of senescence in development and cell plasticity	58
Inflammation-targeted nanomedicine against brain cancer: From design strategies to future developments	58
Contributions of the distinct biophysical phenotype of polyploidal giant cancer cells to cancer progression	57
Precision diagnostics in lymphomas – Recent developments and future directions	57
Editorial Board	57
Alternative splicing in EMT and TGF-β signaling during cancer progression	56
Cathepsins: Emerging targets in the tumor ecosystem to overcome cancers	56
Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?	56
Microbiome unlocks cancer immunotherapeutic potential: State of the art and future	56
Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspective	56
Putting the brakes on tumorigenesis with snake venom toxins: New molecular insights for cancer drug discovery	55
The Warburg effect: The hacked mitochondrial-nuclear communication in cancer	54
Mechanisms and strategies of immunosenescence effects on non-small cell lung cancer (NSCLC) treatment: A comprehensive analysis and future directions	54
Gut microbiota and immunosenescence in cancer	54
cGAS/STING signalling pathway in senescence and oncogenesis	53
Emerging role of pancreatic stellate cell-derived extracellular vesicles in pancreatic cancer	53
Transcriptional factors targeting in cancer stem cells for tumor modulation	53
Remodeling of tumor microenvironment by cellular senescence and immunosenescence in cervical cancer	53
Artificial intelligence aids in development of nanomedicines for cancer management	53
The altered lipidome of hepatocellular carcinoma	52
Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance	52
Impaired cholesterol and LDL uptake pathways in the development of oncological and cardiovascular diseases	52
Vitamin D: What role in obesity-related cancer?	52
Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities	52
The role of surgery in platinum-resistant ovarian cancer: A call to the scientific community	51

Editorial Board	51
Corrigendum to “How far have we explored fungi to fight cancer?” [86/Part 2 (2022) 976–989]	51
Editorial Board	50
Editorial Board	50
Pancreatic neuroendocrine neoplasms (pNENs): Genetic and environmental biomarkers for risk of occurrence and prognosis	49
Targeting oncogenic transcription factors in skin malignancies: An update on cancer stemness and therapeutic outcomes	49
Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs)	49
Pro-tumoral functions of tumor-associated macrophage EV-miRNA	49
Regulation of cancer cell signaling pathways as key events for therapeutic relevance of edible and medicinal mushrooms	48
Predictive biomarkers for response to immune checkpoint inhibition	48
Minimal residual disease in advanced or metastatic solid cancers: The G0-G1 state and immunotherapy are key to unwinding cancer complexity	48
The role of exercise in obesity-related cancers: Current evidence and biological mechanisms	47
Inflammation targeted nanomedicines: Patents and applications in cancer therapy	47
New insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy	46
“Time” for obesity-related cancer: The role of the circadian rhythm in cancer pathogenesis and treatment	46
Exploiting transcription factors to target EMT and cancer stem cells for tumor modulation and therapy	46
Small cell lung cancer: Novel treatments beyond immunotherapy	46
Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy	45
Interplay of ferroptosis, cuproptosis, and PANoptosis in cancer treatment-induced cardiotoxicity: Mechanisms and therapeutic implications	45
Dysregulated FOXM1 signaling in the regulation of cancer stem cells	45
Precision medicine in pediatric solid cancers	45
Epigenetic deregulation in cancer: Enzyme players and non-coding RNAs	45
Nanoparticles: Attractive tools to treat colorectal cancer	45
Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways	45